Avadel Issuance Of Capital Stock from 2010 to 2025

AVDL Stock  USD 8.00  0.33  3.96%   
Avadel Pharmaceuticals Issuance Of Capital Stock yearly trend continues to be quite stable with very little volatility. Issuance Of Capital Stock may rise above about 176.4 M this year. From the period between 2010 and 2025, Avadel Pharmaceuticals, Issuance Of Capital Stock regression line of its data series had standard deviation of  74,330,715 and standard deviation of  74,330,715. View All Fundamentals
 
Issuance Of Capital Stock  
First Reported
2010-12-31
Previous Quarter
168 M
Current Value
176.4 M
Quarterly Volatility
74.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Avadel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avadel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 11.9 M or Selling General Administrative of 183.2 M, as well as many indicators such as Price To Sales Ratio of 38.26, Dividend Yield of 0.0 or PTB Ratio of 15.58. Avadel financial statements analysis is a perfect complement when working with Avadel Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.

Latest Avadel Pharmaceuticals' Issuance Of Capital Stock Growth Pattern

Below is the plot of the Issuance Of Capital Stock of Avadel Pharmaceuticals PLC over the last few years. It is Avadel Pharmaceuticals' Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avadel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Issuance Of Capital Stock10 Years Trend
Slightly volatile
   Issuance Of Capital Stock   
       Timeline  

Avadel Issuance Of Capital Stock Regression Statistics

Arithmetic Mean43,811,555
Geometric Mean2,598,877
Coefficient Of Variation169.66
Mean Deviation61,855,832
Median577,000
Standard Deviation74,330,715
Sample Variance5525.1T
Range179.6M
R-Value0.71
Mean Square Error2943.2T
R-Squared0.50
Significance0
Slope11,070,685
Total Sum of Squares82875.8T

Avadel Issuance Of Capital Stock History

2025176.4 M
2024168 M
2023146.1 M
202225.3 M
2021263 K
2020179.7 M
2019118 K

About Avadel Pharmaceuticals Financial Statements

Avadel Pharmaceuticals investors utilize fundamental indicators, such as Issuance Of Capital Stock, to predict how Avadel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Issuance Of Capital Stock168 M176.4 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.09)
Revenue Per Share
1.036
Quarterly Revenue Growth
26.743
Return On Assets
(0.34)
Return On Equity
(1.00)
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.